Press Release Archives - Page 20 of 22

US FDA Approves Spectral Medical’s Protocol Amendment for TIGRIS

Protocol Amendment allows for increase in TIGRIS sites to 15 while potentially accelerating patient enrolling and offsetting any COVID-19 pandemic-related delays Toronto, Ontario | August 10, 2020 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a...

Spectral Medical Provides Corporate Update

Early Tigris trial observations in-line with Euphrates post-hoc results Investigator-driven studies show endotoxin levels significantly elevated in most patients with COVID-induced septic shock Q4 2020 EAA multi-country European launch DIMI traditional FDA 510(k)...

Spectral Medical Inc. Appoints John E. Nosenzo to its Board of Directors

Adds significant experience and strength to the Company’s commercialization focus NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Toronto, Ontario | August 4, 2020 – Spectral Medical Inc. (“Spectral” or the...

Spectral Medical Inc. Files Base Shelf Prospectus

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Toronto, Ontario | July 6, 2020 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for...

Spectral Medical Inc. Files Preliminary Base Shelf Prospectus

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Toronto, Ontario | June 26, 2020 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options...

Spectral Medical Inc. Closes Previously Announced $5.1 Million Public Offering of Units

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Toronto, Ontario | June 18, 2020 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options...

« Older Entries

Next Entries »

EAA™ and PMX are licensed and available for use in Canada. PMX is not approved for clinical use in the USA, and is currently undergoing the PMA (Premarket approval) process. EAA™ is FDA cleared for use in the USA. The information presented herein is region specific. Please contact Spectral Medical Inc.to obtain appropriate product information for your country.